The CEO of Grifols S.A. said Monday evening that his Spanish company’s acquisition of Talecris Biotherapeutics would likely result in minimal job cuts.
Victor Grifols Roura said he expects the total number of jobs eliminated to be less than 5 percent of the 8,500 people Grifols now employs in the U.S. after acquiring Talecris.
“Talecris is a very efficient company,” Grifols said. “We are not coming here with a sword.”
How many of those job cuts might occur in the Triangle, where Talecris employs more than 2,000 people, is unclear.
Grifols has operations in Los Angeles and the merger will create some redundant positions.
But Grifols said his team is interested in keeping the best employees, no matter if they are located in Los Angeles or the Triangle. He said Grifols will maintain a large executive presence in the Triangle.
“I don’t care if they live here or in Los Angeles,” he said.